Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma Patients
The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
Labcorp can now offer a new test that helps doctors find which prostate cancer patients might benefit from a specific medicine. This is a tool that could bring in new business for Labcorp by helping patients get better care.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.